Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.9570 +0.0306 (+3.30%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
34 35 Next >
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Could these biotech companies still win in the vaccine market and beyond? 
Via The Motley Fool
Ocugen to Present at Investing in Cures Summit
From Ocugen
Via GlobeNewswire
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
Via AB Newswire
Topics Intellectual Property
Ocugen Clinical Showcase Webcast Now Available
From Ocugen
Via GlobeNewswire
Recap: Ocugen Q3 Earnings
Via Benzinga
Earnings Outlook For Ocugen
Via Benzinga
Meme Stock Meltdowns: 3 Names to Sell Before They Crash
These once-popular meme stocks are now in free-fall, highlighting the urgent need to offload them from your portfolios. 
Via InvestorPlace
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
From Ocugen
Via GlobeNewswire
Ocugen to Present at 2024 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN
Via AB Newswire
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
Dear OCGN Stock Fans, Mark Your Calendars for Feb. 21
Ocugen stock is rising higher on Tuesday as OCGN fans prepare for a Clinical Showcase tomorrow that could be a positive catalyst for shares. 
Via InvestorPlace
Why Discover Financial Services Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Shares of Discover Financial Services (NYSE: DFS) shares rose sharply in today’s pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic on Tuesday morning as we start the day with a breakdown of all the latest stock market news! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
From Ocugen
Via GlobeNewswire
Ocugen to Present at Pharma Market Research Conference
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
From Ocugen
Via GlobeNewswire
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Q3 2023 Earnings Call Transcript
OCGN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.